Albuterol side effects: what 119,292 FDA adverse event reports show
Drug class
Not stated in label
Who reports
119,292 reports · 68% serious · 10,013 with death outcome · 64% female
Used for
Albuterol tablets, USP are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.
What it is
Albuterol is a member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,161 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Appendicolith | 227 | 264.4 215.0–325.3ROR 264.9 · calibrated p 5e-11 ✓ | 104.1 EB05 93.2 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious n=227 · ♀ 0% (drug 64%) · 100% clinician | no trial arm names this drug |
| Congenital hiatus hernia | 106 | 161.7 124.1–210.8ROR 161.9 · calibrated p 4e-9 ✓ | 82.7 EB05 70.3 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=106 · ♀ 0% (drug 64%) · 100% clinician | no trial arm names this drug |
| Spirometry abnormal | 273 | 153.3 130.3–180.4ROR 153.7 · calibrated p 5e-9 ✓ | 81.2 EB05 73.4 · IC025 +6.0 3/3 methods agree | Lab value / disease marker | serious n=270 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Total lung capacity abnormal | 164 | 133.4 108.8–163.5ROR 133.6 · calibrated p 2e-8 ✓ | 75.0 EB05 65.8 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious n=161 · ♀ 0% (drug 64%) · 100% clinician | no trial arm names this drug |
| Total lung capacity increased | 114 | 126.0 99.0–160.4ROR 126.1 · calibrated p 3e-8 ✓ | 72.4 EB05 61.9 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=114 · ♀ 100% (drug 64%) · 100% clinician | no trial arm names this drug |
| Pulmonary vasculitis | 218 | 123.6 103.9–147.1ROR 123.9 · calibrated p 3e-8 ✓ | 72.0 EB05 64.3 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious n=218 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Mite allergy | 257 | 118.8 101.4–139.2ROR 119.0 · calibrated p 4e-8 ✓ | 70.4 EB05 63.5 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious n=255 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Analgesic therapy | 108 | 95.5 75.5–120.8ROR 95.6 · calibrated p 2e-7 ✓ | 61.2 EB05 52.1 · IC025 +5.3 3/3 methods agree | Reporting / coding artifact | serious n=108 · ♀ 0% (drug 64%) · 100% clinician | no trial arm names this drug |
| Drug therapy | 110 | 92.1 73.0–116.0ROR 92.1 · calibrated p 3e-7 ✓ | 59.8 EB05 51.0 · IC025 +5.3 3/3 methods agree | Reporting / coding artifact | serious n=110 · ♀ 0% (drug 64%) · 100% clinician | no trial arm names this drug |
| Reversible airways obstruction | 172 | 88.3 73.4–106.1ROR 88.4 · calibrated p 3e-7 ✓ | 58.4 EB05 51.4 · IC025 +5.4 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=172 | no trial arm names this drug |
| Dust allergy | 300 | 79.3 69.2–90.9ROR 79.5 · calibrated p 7e-7 ✓ | 54.5 EB05 49.5 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=299 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Mycotic allergy | 262 | 79.2 68.5–91.7ROR 79.4 · calibrated p 7e-7 ✓ | 54.4 EB05 49.1 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=261 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Ejection fraction | 178 | 76.9 64.5–91.8ROR 77.0 · calibrated p 9e-7 ✓ | 53.2 EB05 47.0 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=178 · ♀ 100% (drug 64%) | no trial arm names this drug |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | 154 | 73.8 61.1–89.1ROR 73.8 · calibrated p 1e-6 ✓ | 51.6 EB05 45.2 · IC025 +5.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=152 · 100% clinician | no trial arm names this drug |
| Sensitisation | 224 | 72.6 62.1–84.9ROR 72.7 · calibrated p 1e-6 ✓ | 51.2 EB05 45.8 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=224 · ♀ 100% (drug 64%) | no trial arm names this drug |
| Bronchopulmonary aspergillosis allergic | 267 | 72.2 62.6–83.2ROR 72.3 · calibrated p 1e-6 ✓ | 51.0 EB05 46.1 · IC025 +5.3 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=266 | no trial arm names this drug |
| Bronchial wall thickening | 177 | 56.6 47.8–67.1ROR 56.7 · calibrated p 7e-6 ✓ | 42.7 EB05 37.7 · IC025 +5.0 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=177 | no trial arm names this drug |
| Multiple drug therapy | 162 | 53.0 44.4–63.2ROR 53.1 · calibrated p 1e-5 ✓ | 40.6 EB05 35.6 · IC025 +4.9 3/3 methods agree | Reporting / coding artifact | serious n=160 · ♀ 100% (drug 64%) · 100% clinician | no trial arm names this drug |
| Bronchial secretion retention | 288 | 51.7 45.3–59.0ROR 51.8 · calibrated p 1e-5 ✓ | 39.9 EB05 36.2 · IC025 +5.0 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=281 | no trial arm names this drug |
| Pulmonary function test abnormal | 318 | 44.8 39.6–50.7ROR 44.9 · calibrated p 3e-5 ✓ | 35.7 EB05 32.5 · IC025 +4.9 3/3 methods agree | Reporting / coding artifact | serious n=309 | no trial arm names this drug |
| Antineutrophil cytoplasmic antibody positive | 144 | 43.2 36.0–51.8ROR 43.2 · calibrated p 4e-5 ✓ | 34.6 EB05 30.1 · IC025 +4.7 3/3 methods agree | Lab value / disease marker | serious n=144 · ♀ 0% (drug 64%) · 100% clinician | no trial arm names this drug |
| Full blood count abnormal | 2,076 | 43.0 41.0–45.1ROR 43.7 · calibrated p 3e-5 ✓ | 34.6 EB05 33.4 · IC025 +5.0 3/3 methods agree | Lab value / disease marker | serious PRR 38.7 | no trial arm names this drug |
| Conjunctivitis allergic | 288 | 43.0 37.8–48.9ROR 43.1 · calibrated p 4e-5 ✓ | 34.5 EB05 31.3 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=285 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Eosinophilic granulomatosis with polyangiitis | 331 | 34.3 30.5–38.6ROR 34.4 · calibrated p 1e-4 ✓ | 28.8 EB05 26.3 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=331 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Polycystic ovaries | 257 | 34.2 30.0–39.1ROR 34.3 · calibrated p 1e-4 ✓ | 28.7 EB05 25.9 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=256 · ♀ 100% (drug 64%) | no trial arm names this drug |
| Rhinitis allergic | 703 | 32.9 30.4–35.7ROR 33.1 · calibrated p 2e-4 ✓ | 27.8 EB05 26.1 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=680 · ♀ 89% (drug 64%) | no trial arm names this drug |
| Inhalation therapy | 99 | 32.1 25.9–39.8ROR 32.2 · calibrated p 2e-4 ✓ | 27.1 EB05 22.9 · IC025 +4.3 3/3 methods agree | Reporting / coding artifact | 100% consumer | no trial arm names this drug |
| Obstructive airways disorder | 1,682 | 31.1 29.5–32.7ROR 31.5 · calibrated p 2e-4 ✓ | 26.5 EB05 25.4 · IC025 +4.6 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | age-adj. PRR 29.1 · serious PRR 23.2 | no trial arm names this drug |
| Neuritis | 229 | 30.6 26.6–35.2ROR 30.7 · calibrated p 2e-4 ✓ | 26.1 EB05 23.4 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=227 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Temperature regulation disorder | 311 | 29.0 25.8–32.7ROR 29.1 · calibrated p 3e-4 ✓ | 25.0 EB05 22.7 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=309 · ♀ 100% (drug 64%) | no trial arm names this drug |
| Respiratory symptom | 394 | 28.7 25.8–31.9ROR 28.7 · calibrated p 3e-4 ✓ | 24.7 EB05 22.7 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=388 · ♀ 21% (drug 64%) | no trial arm names this drug |
| Lupus vulgaris | 161 | 27.4 23.2–32.3ROR 27.4 · calibrated p 5e-4 ✓ | 23.7 EB05 20.8 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=161 · ♀ 100% (drug 64%) · 100% clinician | no trial arm names this drug |
| Total lung capacity decreased | 205 | 25.7 22.2–29.7ROR 25.7 · calibrated p 6e-4 ✓ | 22.4 EB05 20.0 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=189 | no trial arm names this drug |
| Sleep disorder due to a general medical condition | 2,012 | 24.9 23.7–26.1ROR 25.3 · calibrated p 6e-4 ✓ | 21.9 EB05 21.1 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 24.3 · serious PRR 34.7 | no trial arm names this drug |
| Obstructive sleep apnoea syndrome | 172 | 24.6 21.0–28.8ROR 24.6 · calibrated p 8e-4 ✓ | 21.6 EB05 19.0 · IC025 +4.1 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=170 | no trial arm names this drug |
| Chest x-ray abnormal | 377 | 24.2 21.8–27.0ROR 24.3 · calibrated p 8e-4 ✓ | 21.4 EB05 19.6 · IC025 +4.2 3/3 methods agree | Lab value / disease marker | serious n=376 | no trial arm names this drug |
| Increased bronchial secretion | 309 | 24.0 21.3–27.0ROR 24.0 · calibrated p 9e-4 ✓ | 21.1 EB05 19.2 · IC025 +4.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=291 · 100% consumer | no trial arm names this drug |
| Forced expiratory volume decreased | 341 | 23.9 21.4–26.8ROR 24.0 · calibrated p 9e-4 ✓ | 21.1 EB05 19.3 · IC025 +4.2 3/3 methods agree | Lab value / disease marker | serious n=334 · ♀ 34% (drug 64%) | no trial arm names this drug |
| Sputum culture positive | 99 | 23.9 19.3–29.5ROR 23.9 · calibrated p 1e-3 ✓ | 21.0 EB05 17.8 · IC025 +3.9 3/3 methods agree | Lab value / disease marker | serious n=99 · ♀ 100% (drug 64%) · 100% clinician | no trial arm names this drug |
| Nasal polyps | 578 | 23.8 21.8–26.0ROR 23.9 · calibrated p 9e-4 ✓ | 21.0 EB05 19.6 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=562 | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Interstitial lung disease | 1,485 | 2.72.6–2.9 | signal |
| Serious infection | 11,359 | 2.62.6–2.7 | signal |
| Hyponatraemia | 1,148 | 2.52.4–2.7 | signal |
| Venous thromboembolism | 3,034 | 2.52.4–2.6 | signal |
| Depression | 3,820 | 2.42.3–2.5 | signal |
| Heart failure | 2,312 | 2.32.2–2.4 | signal |
| Arrhythmia / qt | 2,495 | 2.32.2–2.4 | signal |
| Anaphylaxis / angioedema | 1,562 | 2.22.1–2.3 | signal |
| Gi bleeding | 2,137 | 2.12.0–2.2 | raised |
| Kidney injury | 4,989 | 1.91.9–2.0 | raised |
| Tendon disorder | 395 | 1.81.7–2.0 | raised |
| Fall / fracture | 3,805 | 1.81.7–1.8 | raised |
| Anaemia | 2,907 | 1.71.6–1.8 | raised |
| Pancreatitis | 758 | 1.71.5–1.8 | raised |
| Hyperglycaemia / diabetes | 3,153 | 1.61.6–1.7 | raised |
| Myocardial infarction | 1,849 | 1.61.5–1.7 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Dyspnoea (shortness of breath) | 16,618 | 5.3 5.2–5.4ROR 6.0 · calibrated p 0.151 | 5.2 EB05 5.1 · IC025 +2.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 4.6 · serious PRR 4.5 | no trial arm names this drug |
| Asthma | 9,658 | 16.5 16.2–16.8ROR 17.9 · calibrated p 0.003 ✓ | 15.1 EB05 14.9 · IC025 +3.9 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 16.7 · serious PRR 15.3 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 9,254 | 1.2 1.2–1.3ROR 1.3 · calibrated p 0.478 | 1.2 EB05 1.2 · IC025 +0.3 | Reporting / coding artifact | age-adj. PRR 1.4 · serious PRR 1.6 | no trial arm names this drug |
| Cough | 7,671 | 4.9 4.8–5.0ROR 5.2 · calibrated p 0.214 | 4.8 EB05 4.7 · IC025 +2.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 4.5 · serious PRR 5.3 | no trial arm names this drug |
| Pneumonia (lung infection) | 7,252 | 4.0 3.9–4.1ROR 4.2 · calibrated p 0.341 | 3.9 EB05 3.9 · IC025 +1.9 3/3 methods agree | Not in label — unassessed | age-adj. PRR 3.5 · serious PRR 3.4 | no trial arm names this drug |
| Nausea | 7,074 | 1.6 1.5–1.6ROR 1.6 · calibrated p 0.717 | 1.6 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.8 | no trial arm names this drug |
| Fatigue (tiredness) | 7,005 | 1.6 1.6–1.6ROR 1.6 · calibrated p 0.723 | 1.6 EB05 1.6 · IC025 +0.6 | Not in label — unassessed | age-adj. PRR 1.5 · serious PRR 1.8 | no trial arm names this drug |
| Headache | 6,827 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.934 | 1.9 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 2.4 | no trial arm names this drug |
| Off label use (used outside approved label) | 6,345 | 1.3 1.3–1.3ROR 1.3 · calibrated p 0.510 | 1.3 EB05 1.3 · IC025 +0.3 | Reporting / coding artifact | age-adj. PRR 1.2 · serious PRR 1.4 | no trial arm names this drug |
| Pain | 6,100 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.824 | 1.7 EB05 1.7 · IC025 +0.8 | Not in label — unassessed | age-adj. PRR 2.0 · serious PRR 1.9 | no trial arm names this drug |
| Wheezing | 5,493 | 17.9 17.4–18.4ROR 18.7 · calibrated p 0.003 ✓ | 16.3 EB05 16.0 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 17.3 · serious PRR 16.2 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 5,287 | 1.4 1.4–1.5ROR 1.5 · calibrated p 0.621 | 1.4 EB05 1.4 · IC025 +0.5 | Not in label — unassessed | age-adj. PRR 1.4 · serious PRR 1.6 | no trial arm names this drug |
| Vomiting | 4,845 | 1.8 1.8–1.9ROR 1.9 · calibrated p 0.865 | 1.8 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 1.9 | no trial arm names this drug |
| Dizziness | 4,747 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.776 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.9 | no trial arm names this drug |
| Anxiety | 4,386 | 2.7 2.6–2.8ROR 2.8 · calibrated p 0.697 | 2.7 EB05 2.6 · IC025 +1.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.9 · serious PRR 2.9 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Appendicolith — n=227, PRR 264.4
- Congenital hiatus hernia — n=106, PRR 161.7
- Total lung capacity abnormal — n=164, PRR 133.4
- Total lung capacity increased — n=114, PRR 126.0
- Pulmonary vasculitis — n=218, PRR 123.6
- Mite allergy — n=257, PRR 118.8
- Dust allergy — n=300, PRR 79.3
- Mycotic allergy — n=262, PRR 79.2
- Ejection fraction — n=178, PRR 76.9
- Sensitisation — n=224, PRR 72.6
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Albuterol?
In FDA FAERS, the most frequently co-reported reaction terms for Albuterol are dyspnoea, asthma, cough, pneumonia, nausea, fatigue. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Albuterol have an FDA boxed warning?
No. The FDA label retrieved for Albuterol has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Albuterol causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 230d66fc-f62c-42a6-adb3-0a0f879c8ad4, effective 20260414; matched on
openfda.generic_name.exact:"ALBUTEROL" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 2083 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,201 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
ALBUTEROL, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.